Plasma Cholinesterase Activity in Alzheimer's Disease

Authors:
  • KHKoji Hori
    Koji Hori
  • KKKimiko Konishi
    Kimiko Konishi
  • MTMasayuki Tani
    Masayuki Tani
  • HTHiroi Tomioka
    Hiroi Tomioka
  • YKYuka Kitajima
    Yuka Kitajima
  • NANorihisa Akashi
    Norihisa Akashi
  • AIAtsuko Inamoto
    Atsuko Inamoto
  • SMSousuke Minami
    Sousuke Minami
  • TITakuji Izuno
    Takuji Izuno
  • KUKaori Umezawa
    Kaori Umezawa
  • KHKentaro Horiuchi
    Kentaro Horiuchi

Abstract
Cholinesterase inhibitors (ChEIs) are not allowed to be prescribed in combination, which means that we need to select 1 of 3 ChEIs for use in a patient with Alzheimer's disease (AD). However, there is no quantitative analysis on the differences between these agents. In this article, we propose that plasma cholinesterase activity (pChE) could be used as the standard for differentiating between rivastigmine (Riv) and donepezil (Don) in the management of AD. To date, we have treated 6 patients with Riv 18 mg and 5 patients with Don 5 mg. The pChE is related to low-grade inflammation associated with AD, diabetes mellitus and lipid metabolic dysfunction. Moreover, low pChE is related to liver dysfunction. The pChE must be kept under control. We speculated that Riv is the most appropriate therapy for patients with relatively high pChE, whereas Don is best reserved for those AD patients with relatively low pChE.

This publication has 13 references indexed in Scilit: